 CAMBRIDGE, Mass., June 14, 2021 GLOBE NEWSWIRE -- Sigilon Therapeutics, Inc. NASDAQ:SGTX, a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living TherapeuticsTM platform, today announced the appointment of Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer CSO. Most recently, Dr. Ashton-Rickardt served as Senior Vice President for Immunology at AZTherapies, Inc., where he was responsible for preclinical development of cell therapies, biologic and small molecule platform technologies to treat neurodegenerative diseases. 